#### 1 Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease between 2009 and 2021 in England 2

- Authors: Rutendo Muzambi<sup>ab</sup>, Krishnan Bhaskaran<sup>a</sup>, Helen Strongman<sup>a</sup>, Tjeerd van 3
- Staa<sup>c</sup>, Liam Smeeth<sup>b</sup>, Emily Herrett<sup>a</sup> 4

#### **Affiliations:** 5

- <sup>a</sup> Faculty of Epidemiology and Population Health, London School of Hygiene and 6
- Tropical Medicine, London, WC1E 7HT, UK 7
- <sup>b</sup> Faculty of Epidemiology and Biostatistics, School of Public Health, Imperial College 8
- London, London, W12 0BZ, UK 9
- 10 <sup>c</sup>Centre for Health Informatics, Division of Informatics, Imaging and Data Science,
- Faculty of Biology, Medicine and Health, School of Health Sciences, The University of 11
- Manchester, Manchester Academic Health Science Centre, Vaughan House, Manchester, 12
- 13 M13 9PL, UK.
- 14

#### Abstract 15

- **Objective** To investigate trends and inequalities in statin use for the primary and 16
- secondary prevention of cardiovascular disease (CVD) 17
- **Design** Repeated cross-sectional and historical cohort study designs 18
- Setting English primary care electronic health records from the Clinical Practice 19
- 20 Research Datalink (CPRD Aurum) linked to Hospital Episode Statistics Admitted Patient Care 21
- Participants 5 million adults aged 25 years and older randomly sampled from CPRD 22 Aurum between 1<sup>st</sup> April 2009 and 31<sup>st</sup> December 2021. 23
- 24 **Outcome measures** Monthly proportion of current statin users; adjusted odds ratios
- 25 (aOR) for statin initiation; adjusted hazard ratios (aHR) for cardiovascular risk
- assessment, statin discontinuation and statin re-initiation and number of CVD events 26
- prevented with optimal statin use and estimated costs saved. 27

#### **Results** 28

The overall monthly proportion of individuals prescribed statins for primary prevention 29 30 increased from 22.3% in 2009 to 35.6% in 2021 among those aged 70+ years, and was stable in other age groups. The proportion of eligible individuals receiving a statin for 31 secondary prevention was higher in all age groups (e.g. increasing from 68.1% to 73.7%) 32 over the same period, in those aged 70+). Overall prevalence of statin use was lowest 33 34 among women, 25-39 age group, and black, mixed, and other ethnic groups for both primary and secondary prevention. Monthly proportion of CVD risk assessment, among 35 those eligible, increased from 13.7% in May 2009 to 31.8% by November 2021. 79.0% 36 of individuals were initiated statins within 60 days of a CVD event. Women (aOR 0.70; 37 38 95% CI, 0.68 – 0.72) and people of black ethnicity (aOR 0.71; 95% CI, 0.65-0.77) were less likely to be initiated statins compared to those of white ethnicity while people of 39 south Asian ethnicity (aOR 1.53; 95% CI, 1.42-1.64) were more likely to be initiated 40 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to quide clinical practice. stating than white people for secondary prevention. Statin discontinuation was most 41

- 42 likely among women (aHR 1.08, 95% CI; 1.06–1.11) black people (aHR 1.76, 95% CI,
- 1.65–1.89) and the most deprived group (aHR 1.08, 95% CI; 1.04–1.12) compared to 43
- men, white people and the least deprived group, respectively, for primary prevention 44
- with similar associations seen for secondary prevention for ethnicity and deprivation. 45
- With optimal statin treatment, over 150,000 cardiovascular events could be prevented 46 in the next 10 years for primary prevention and 5 years for secondary prevention 47
- resulting in a potential saving to the health service of over £400 million in those eligible 48
- for statins. 49

#### 50 Conclusion

- Statin use remains suboptimal and inequalities particularly among women, people of 51
- black ethnicity and those in the most deprived socioeconomic groups persist across 52
- multiple stages of statin use for both primary and secondary prevention. To reduce 53
- these inequalities and avoid missed opportunities to prevent cardiovascular events and 54
- costs to the NHS, strategies are needed specifically targeting these patient groups to 55
- reduce the burden of CVD. 56
- 57

58

59	Summary box	
60		
61	Section 1: What is already known on this topic	
62	• Previous studies have shown that statins are under-prescribed and under-used	
63	in both primary and secondary prevention of cardiovascular disease (CVD)	
64	resulting in missed opportunities to reduce CVD burden.	
65	• Few studies have examined trends in statin use in recent years, including during	
66	the pandemic period.	
67	• Inequalities in statin use based on age, gender, ethnicity and deprivation have	
68	been identified previously, however it is unclear where, along the pathway from	
69	identification of eligible patients to initiation and continuation of statins, these	
70	inequalities manifest.	
71	Section 2: What this study adds	
72	• Levels of CVD risk assessment were suboptimal throughout the study period: a	
73	modest increase in the proportion of eligible individuals with a CVD risk	
74	assessment from $14\%$ in May 2009 to $35\%$ in February 2020 was followed by a	
75	decline during the COVID-19 pandemic.	
76	• Prevalence of statin use increased between 2009 and 2021 but remained	
77	suboptimal throughout, and with important sociodemographic disparities.	
78	Women and people of black ethnicity were less likely to initiate statins for	
79	secondary prevention compared to men and the white ethnic group while people	
80	of south Asian ethnicity and the 60-69 age group were more likely to initiate	
81	statins compared to people of white ethnicity and the 25-39 age group,	

83	•	Statin discontinuation was higher among women than men (secondary
84		prevention only), black ethnic groups compared to white ethnic groups, and the
85		most deprived socioeconomic groups compared to the least deprived for both
86		primary and secondary prevention.
87	•	We estimated that over 100,000 cardiovascular events could be prevented in the
88		next 10 years if the observed missed opportunities for statin use in primary CVD
89		prevention among eligible individuals were fully addressed, and a further 50,000
90		events could be prevented over 5 years for secondary prevention. The
91		consequent potential saving to the health service was estimated to be over £400
92		million.
93		
94		
95		

96

## **Summary of main results**

## 99 Overall prevalence of statin use

There was a small increase in the overall monthly prevalence of statin users between May 2009
and November 2021 ranging from 8.5% to 10.7% and 67.4 to 71.8% for primary prevention and secondary prevention, respectively. Monthly prevalence of statins was lowest among the Black,
Mixed and Other ethnicity groups and among those in the most deprived socioeconomic groups

103 (primary prevention only).

## Sociodemographic disparities along the pathway of statin use

## 105

104

## 106 CVD risk assessment

107 South Asian (HR 1.39, 95% CI:1.38-1.40), Black (HR 1.28, 95% CI:1.27-108 1.29) and Mixed (HR 1.15, 95%) CI:1.13-1.17) ethnic groups, as well 109 as individuals in the most deprived socioeconomic groups (HR 1.23, 110 95% CI:1.22-1.24), were more 111 likely to receive a CVD risk assessment compared to the White 112 ethnic group and least deprived 113 socioeconomic group.

## 114

## Initiation

For secondary prevention, statin initiation was least likely among the Black ethnic group compared to the White group (OR 0.71, 95% CI: 0.65-0.77) and women compared to men (OR 0.70, 95% CI, 0.68 - 0.72). Statin initiation was highest among the South Asian group compared to the White group (OR 1.53, 95% CI, 1.42-1.64). Among those with a recorded risk score above threshold. statin initiation was least likely in the 70+ age group than the 40-49 age group (OR 0.75, 95%) CI, 0.72 – 0.79) and people of black ethnicity than white ethnicity (OR 0.82, 95% CI: 0.77 - 0.88).

## Discontinuation

For primary prevention, the Black ethnic group (HR 1.76, 95% CI: 1.65-1.89) and those in the most deprived socioeconomic group (HR 1.08, 95% CI: 1.04-1.12) were more likely to discontinue statins compared to the White group and those in the least deprived group, respectively. In secondary prevention, these associations were also observed and in addition women were more likely to discontinue statins compared to men (HR 1.08, 95% CI: 1.06-1.11).

## Reinitiation

Black and South Asian ethnic groups, those in the most deprived socioeconomic group and the 70+ age group were more likely to re-initiate statins compared to the White ethnic group, least deprived group and the 25-39 age group, respectively, for both primary and secondary prevention. Women were less likely to reinitiate statins compared to men, particularly in secondary prevention HR 0.87 (95% CI, 0.85 – 0.90).

## 115 Introduction

- 116 Cardiovascular disease (CVD) is the leading cause of morbidity and mortality
- worldwide, accounting for 32% of all global deaths in 2019 and a quarter of all deaths in
- the UK.(1, 2) Statins have been proven to be effective in reducing cardiovascular events
- and are widely prescribed, with atorvastatin the most commonly dispensed medication
- 120 in England between 2022 and 2023. (3-5)
- 121 Despite National Institute for Health and Care Excellence (NICE) guidelines
- 122 recommending the use of statins in those at risk of CVD and to all individuals with a
- 123 prior CVD event, evidence suggests that statins are under-prescribed, with previous
- studies showing that only 30-50% of adults at high risk of CVD in the UK were receiving

statins.(6-9) Coverage of CVD risk assessment is low and studies investigating trends in

- 126 CVD risk assessment in more recent years including during the COVID-19 pandemic are
- 127 lacking and evidence on inequalities in risk assessment is limited.(10)
- Disparities in statin prescribing in terms of age, gender, ethnicity and deprivation have
  been highlighted previously.(7, 11-17) However, it is unclear where along the pathway
  from identification of eligible patients, statin initiation and continued statin use these
  inequalities manifest. Missed opportunities for treatment are associated with worsening
  of clinical outcomes, mortality and higher healthcare costs.(14, 18, 19)
- Therefore, we examined trends and factors (age, gender, ethnicity, and deprivation)
  associated with statin prevalence, cardiovascular risk scoring, initiation (among those
  with an above threshold CVD risk score for primary prevention or existing CVD event
  for secondary prevention), discontinuation, and re-initiation of statins between 1<sup>st</sup> April
  2009 and 31<sup>st</sup> December 2021. We also estimated the number of cardiovascular events
  that could be prevented and healthcare cost savings with optimal statin use.

## 139 Methods

141

## 140 Data and participants

We conducted a several cross-sectional and historical cohort studies using data from

- 142 the Clinical Practice Research Datalink (CPRD Aurum) linked to Hospital Episode
- 143 Statistics (HES) Admitted Patient Care. (20, 21) CPRD Aurum database consists of
- 144 pseudonymous electronic health records from UK primary care practices using the EMIS
- 145 general practice (GP) electronic health record software. The CPRD Aurum January 2022
- 146 build was used to extract the cohort for this study. CPRD Aurum contained over 40
- 147 million individuals and 1,489 GP practices.(22) The database includes information on
- 148 patient and practice demographics, diagnoses and symptoms, medication prescriptions,
- 149 and referrals. Our study followed the Reporting of Studies Conducted Using
- 150 Observational Routinely Collected Data reporting guidelines.(23)
- 151 Our overall study population included 16,650,277 individuals aged 25 years and older
- between 1st April 2009 and 31st December 2021 eligible for HES linkage and at least 12
- 153 months research standard follow up in CPRD Aurum (Supplementary Figure 1). From
- this population, we extracted data from a random sample of 5 million individuals and
- 155 details of the random sample can be found in the Supplementary Methods and
- 156 Supplementary Table 1. Our study period was from April 2009 as this corresponds to
- 157 when NHS health checks, which assess CVD risk and can inform statin prescribing, were
- 158 first introduced.(24) Start of follow up for the overall cohort was defined as the latest of
- 159 1<sup>st</sup> April 2009, 25<sup>th</sup> birthday and 12 months after current registration in the CPRD
- practice. End of follow-up was the earliest of 31<sup>st</sup> December 2021, death date or end of
  follow-up in CPRD.

- 162 We used SNOMED codes in CPRD and ICD-10 codes in HES to identify CVD diagnoses
- 163 and covariates. Statin prescription information was obtained in CPRD using Dictionary
- 164 of Medicines and Devices (dm+d) codes.

## 165 Figure 1. Conceptual figure depicting typical pathway of statin use



- 166 Figure 1 shows a conceptual figure of the pathway of statin use. The overall prevalence
- 167 of statin use for primary and secondary prevention is the result of identification of
- 168 eligible individuals, initiation and continued use of statins. Our study seeks to determine
- 169 where, and in whom, along this pathway are there inequalities in statin treatment and
- 170 thus are opportunities for CVD prevention being missed.
- 171 Our subpopulation cohorts are described below.

## 172 Study population and statistical analyses

## 173 CVD risk scoring

- 174 We included individuals without a CVD diagnosis aged between 25-84 years old. We
- 175 described the characteristics of individuals formally risk scored by their GP using all
- available CVD risk assessment tools (QRISK, QRISK2, Framingham, Joint British Society,
- 177 ASSIGN, or unspecified).(25-28) Then, we described the monthly proportion of
- 178 individuals with a recorded cardiovascular risk score in the last 5 years, between May
- 179 2009 and December 2021, and stratified by CVD risk tool, CVD risk category as assessed

by the GP (<10%, 10-19% and 20%), age, gender, ethnicity, and deprivation. Individuals 180 were excluded from a monthly denominator when they were diagnosed with a CVD 181 event, became ineligible for CVD risk assessment (e.g. CKD, T1DM or familial 182 hypercholesterolaemia diagnosis) or were initiated on statins. Individuals were defined 183 as having a current CVD risk record if they had a risk record in the last 5 years 184 (corresponding to the recommended frequency of CVD risk assessment). (24) If 185 individuals had multiple CVD risk scores on the same date, we kept the highest score. 186 To determine which individuals were eligible for CVD risk assessment, we included 187 individuals aged 40-74 years (in accordance with the NHS health check age criteria), 188 with no history of CVD, chronic kidney disease (CKD), type 1 diabetes mellitus (T1DM), 189 familial hypercholesterolaemia and no contraindications to statins. Cox proportional 190 hazards regression models, with the start of follow up as the time scale, were used to 191 estimate hazard ratios (HRs) for the association between demographic variables (age at 192 start of follow up, gender, ethnicity, and deprivation) and receiving a CVD risk score 193 from the GP. Start of follow up was defined as the latest of 1<sup>st</sup> April 2009, 40<sup>th</sup> birthday 194 and 12 months after current registration in CPRD. Individuals were followed until the 195 earliest of CVD risk assessment, 75<sup>th</sup> birthday, CVD event or ineligibility for CVD risk 196 assessment. We adjusted for demographic variables mentioned above as these factors 197 are likely to be fixed. We had insufficient time-updated information to adjust for time-198 dependent variables. 199

## 200 Statin prevalence

To describe the prevalence of statin use for primary CVD prevention, we included
individuals without prior CVD (e.g. past or current history of myocardial infarction,
angina, revascularisation procedures, stroke, transient ischaemic attack, or peripheral

arterial disease). For secondary prevention, our cohort included individuals with
existing CVD. We excluded individuals contraindicated to statins (using SNOMED codes
for liver disease or codes explicitly stating statin contraindication) in both cohorts. An
individual was defined as a current statin user if they had an ongoing statin prescription
based on the number of days prescribed, allowing for a grace period of 28 days between
prescriptions.

210 We described the proportion of individuals with a current statin prescription each calendar month for primary and secondary prevention. In subgroup analyses, monthly 211 prevalence was stratified by age (25-39, 40-49, 50-59, 60-69, 70-79, 80+), gender (men 212 and women), ethnicity, (white, South Asian, black, mixed and other), deprivation (using 213 linked patient-level Townsend deprivation scores, categorised into quintiles) and CVD 214 subtype (for secondary prevention). Individuals left both prevalence cohorts when they 215 had a statin contraindication and left the primary prevention cohort when they were 216 diagnosed with a CVD event. 217

## 218 Statin initiation

To assess initiation of statins for primary prevention, we included individuals aged 40-219 74 who were eligible for the NHS health check and had a recorded CVD risk score above 220 the threshold for statin initiation, with no history of CVD, CKD, T1DM or familial 221 hypercholesterolaemia. We included the first recorded CVD risk score, within follow-up, 222 that was eligible for statin initiation where there was no previous statin prescription. 223 Consistent with NICE guidelines, those with a 20% or higher 10-year risk of CVD before 224 2014 and a 10% or higher 10-year risk of CVD after 2014, were considered above the 225 treatment threshold and eligible for statin initiation.(29) Statin initiation was defined as 226

having a first statin prescription within 28 days of a first recorded CVD risk score abovetreatment threshold.

Our secondary prevention initiation cohort comprised individuals with a CVD event 229 who remained alive and under follow-up within 60 days of a CVD event and with no 230 statin contraindications. Statin initiation was defined as having a first statin 231 prescription within 60 days of a CVD event. We chose a 60-day grace period between 232 233 the first cardiovascular event and subsequent statin prescription to account for individuals who may be initiated statins in secondary care and may wait until they have 234 completed their prescription before obtaining a statin prescription in primary care. 235 We used Kaplan Meier curves to examine the time from first CVD risk score above 236 threshold to statin initiation (primary prevention) or time from CVD event to statin 237 238 initiation (secondary prevention). These curves were stratified by age, gender, ethnicity, deprivation, CVD risk score (primary prevention only) or CVD subtype (secondary 239 240 prevention only). Individuals were censored at end of follow up (including death), CVD event (primary prevention only) and statin contraindication (e.g. liver disease). We 241 used logistic regression to examine the factors associated with initiating a statin for 242 primary and secondary prevention within 28 days of becoming eligible. We adjusted for 243 244 age at risk assessment (primary prevention) or age at CVD diagnosis (secondary prevention), gender, ethnicity, deprivation, Body Mass Index (BMI,  $kg/m^2$ ) 245 246 (underweight, normal weight, overweight, obese or morbidly obese), smoking status (non-smoker, current smoker and former smoker), treated hypertension (defined as 247 248 antihypertensives prescribed on the date of or after hypertension diagnosis), type II diabetes mellitus (T2DM), atrial fibrillation and rheumatoid arthritis. We did not adjust 249 for HDL, LDL, total cholesterol, and systolic and diastolic blood pressure due to 250

- 251 moderate/high levels of missingness (Supplementary Table 2) and chronic kidney
  252 disease (in primary prevention analyses) as CVD risk assessment is not recommended
- in this population for primary prevention.

## 254 Statin discontinuation

255 We included all individuals aged 25 years and older who had initiated statins for

- 256 primary prevention (all individuals without pre-existing CVD event) and secondary
- 257 prevention (all individuals with a first CVD event during the study period). After
- individuals reached the end of their prescription based on the date of prescription, dose
- and quantity prescribed, statin cessation was defined as reaching the end of a 90-day
- 260 grace period without a new statin prescription, to allow time for those with overlapping
- 261 prescriptions to use their excess supply.
- 262 We used Kaplan Meier curves to examine the time from statin initiation to
- discontinuation stratified by age, gender, ethnicity, deprivation, CVD risk category
- 264 (primary prevention) or CVD subtype (secondary prevention). Cox proportional

hazards regression models, with date of statin initiation as the time scale, were used to

estimate hazard ratios (HRs) for the association between demographic variables (age at

statin initiation, gender, ethnicity, and deprivation) and statin discontinuation, adjustedfor these demographic variables.

## 269 Statin re-initiation

266

Our re-initiation cohort included all individuals who had discontinued statins based on
criteria mentioned above. For our primary prevention cohort, we additionally excluded
individuals with a CVD diagnosis prior to statin cessation. Statin re-initiation was
defined as receiving a subsequent statin prescription after a 90-day period without a

statin prescription, starting from the time when the last prescription ran out (estimated
based on date of previous prescription, dose and quantity of tablets prescribed).

We used Kaplan Meier curves to examine time from statin discontinuation to first
subsequent statin prescription. We stratified by age at discontinuation date, gender,
ethnicity, deprivation, CVD risk category or CVD subtype. We used Cox proportional
hazards regression models, with date of statin discontinuation as the time scale, to
estimate hazard ratios (HRs) for the association of age, gender, ethnicity, and
deprivation with statin discontinuation, adjusting for these demographic variables.

## 282 Healthcare costs

We used the National Schedule of NHS (National Health Service) costs to calculate the
cost of CVD events for the year of 2021-22 for all NHS trusts and NHS foundation trusts
and all healthcare resource groups (Supplementary Table 3). (30) We also used the
prescription cost analysis dataset for the financial year 2021-22 which includes the
costs of medications dispensed in the community in England (Supplementary Table
4).(31)

To calculate the number of additional cardiovascular events avoided over 10 years with 289 optimal statin use for each risk category, we calculated the 10-year total number of 290 expected events from the CVD risk, based on the recorded risk scores among those with 291 a CVD risk assessment, and number of individuals not taking statins, and applied a 25% 292 risk reduction due to stating for those without vascular disease.(32) For secondary 293 prevention, we calculated the number of cardiovascular events avoided over 5 years 294 with optimal statin use for each CVD event among those eligible but not taking statins, 295 using a 10% absolute benefit.(4) We then scaled these analyses to the English 296 population using data from the 2021 census of adults aged 25 years and older 297

(N=40,017,720).(33) We calculated the total cost of recommended statin dose for
primary and secondary prevention (atorvastatin 20mg and atorvastatin 80mg)
according to the British National Formulary using the total population not prescribed
statins, total quantity, and cost per quantity from the 2021/22 English prescription cost
analysis dataset. (31)

## 303 Additional secondary and sensitivity analyses

We performed a range of secondary and sensitivity analyses. First, we stratified our 304 initiation, discontinuation, and re-initiation analyses by the pre-pandemic (before 305 01/03/2020) and pandemic period (from 01/03/2020) to examine the effect of the 306 COVID-19 pandemic. Second, we expanded our definition for statin initiation from a first 307 statin prescription within 28 days after above threshold risk score to 90 days for 308 309 primary prevention and from a statin prescription within 60 days after first CVD event to 90 days for secondary prevention. The rationale for this was to minimise 310 311 misclassification of statin initiators. Third, to minimise misclassification of statin discontinuation, we expanded our definition of cessation from a 90-day grace period to 312 180 days. 313

## 314 Model Checking

We found evidence of non-proportionality when we tested the Cox proportional hazards assumption using Schoenfeld residuals test and log-log plots for our analyses on factors associated with receiving a CVD risk score, statin discontinuation and statin reinitiation. To deal with this, we performed sensitivity analyses in which we added interaction terms between non-proportional demographic factors and time.

- All analyses were conducted in R Studio, version 4.3.2. Numerical estimates of monthly
- 321 proportions of statin users and individuals with CVD risk assessments as well as

number of people at risk and events for the Kaplan Meier plots can be found on Github:

323 <u>https://github.com/RutendoMuzambi/trends statin use</u>.

## 324 Patient and Public Involvement Statement

No patients were involved in setting the research question or outcome measures, or thedesign or implementation of this study.

## 327 Results

In our random subsample of 5 million individuals aged 25 years and older from a total 328 population of 16.6 million individuals eligible for inclusion into the present study 329 (Supplementary Figures 2 and 3), 4,606,274 and 416,431 individuals were included in 330 the primary and secondary prevention cohorts specifically on statin use, respectively 331 (Table 1A and 1B). Overall, individuals included in the primary prevention cohort were 332 younger (median: 39.0 years [IQR, 29.0 to 53.0] vs 70.0 years [IQR, 59.0 to 79.0] and 333 there was a higher proportion of women (50.8% vs 43.1%) than in the secondary 334 prevention cohorts. We also present characteristics of individuals included in four sub-335 336 cohorts for prevalence, initiation, discontinuation, and re-initiation analyses in Table 1A 337 and 1B. Of the 303,292 and 122,743 people in total who initiated statins during the study, 116,468 (38.4%) and 27,257 (22.2%) discontinued statins for primary and 338 secondary prevention respectively (Supplementary Figures 2 and 3). Of these, 115,043 339 (79.5%) and 24,876 (91.3%) re-initiated statins for primary and secondary prevention 340 respectively. Baseline characteristics of individuals included in the CVD risk assessment 341 sub-cohorts on monthly prevalence of individuals with a CVD risk assessment and 342 343 factors associated with a CVD risk assessment are presented in Supplementary Table 5.

344

## Table 1A and 1B

#### Trends across time in statin prevalence 345

Between May 2009 and November 2021, there was a small increase in the monthly 346 347 proportion of statin users over time, ranging from 8.5% - 10.7% and 67.4-71.8% for primary prevention and secondary prevention, respectively (Figure 2). The increase in 348 statin prevalence for primary prevention appears to be driven largely by the 70+ age 349 group whose monthly proportion of statin users increased from 22.3% - 35.6% between 350 May 2009 and November 2021. During this period an increase in this age-group from 351 68.1% to 73.7% was seen for secondary prevention. In both cohorts, the monthly 352 proportion of statin users was lowest among women, 25-39 age group, in those of black, 353 mixed, and other ethnic groups, the most deprived group (primary prevention only) but 354 355 highest in those with a history of myocardial infarction (secondary prevention only).

356

## Figure 2

#### Trends across time in cardiovascular risk scoring 357

358 The monthly proportion of individuals with a GP recorded CVD risk assessment, regardless of eligibility for risk assessment, rose steadily from 13.7% in May 2009 to 359 360 35.3% in February 2020 and declined to 31.8% by November 2021 (Supplementary Figure 4). The proportion of CVD risk assessments, performed by GPs, was highest in 361 the 40-74 age group and among those with less than 10% CVD risk score. Figure 3 362 shows that CVD risk assessment was most likely among the 70-74 age group compared 363 364 to 40-49 age group adjusted HR 2.62 (95% CI, 2.60 – 2.65) and those of South Asian ethnicity adjusted HR 1.39 (95% CI, 1.38 – 1.40), Black ethnicity adjusted HR 1.28 (95% 365 CI, 1.27-1.29) and Mixed ethnicity adjusted HR 1.15 (95% CI, 1.13-1.17) compared to 366

white ethnicity. While there was no apparent trend across 4 lowest quintiles of
deprivation, the most deprived group was more likely to receive a CVD risk assessment
than the least deprived group adjusted HR 1.23 (95% CI, 1.22 – 1.24).

370

## Figure 3

## 371 Initiation

11.5% (n=49,877) of individuals with recorded risk score above the threshold initiated 372 a statin within 28 days (primary prevention) while 79.0% (n=115,968) of individuals 373 374 with a CVD diagnosis were initiated statins within 60 days of first CVD event (secondary prevention. Figure 4 shows that among individuals with an above threshold recorded 375 CVD risk score, statin initiation was least likely in the 70+ age group than the 40-49 age 376 group (adjusted OR 0.75, 95% CI, 0.72 – 0.79), people of black ethnicity than white 377 ethnicity (adjusted OR 0.82, 95% CI: 0.77 – 0.88) but statin initiation was more likely in 378 those in the most deprived group than in the least deprived group (adjusted OR 1.16, 379 95% CI; 1.12 – 1.20) and among women compared to men (adjusted OR 1.06, 95% CI; 380 1.04 – 1.08). In contrast, for secondary prevention, statin initiation within 60 days of a 381 first CVD event was highest among the 60-69 age group than the 25-39 age group 382 (adjusted OR 3.19, 95% CI; 3.02 – 3.38) and among people of south Asian ethnicity 383 compared to those of white ethnicity (adjusted OR 1.53, 95% CI, 1.42-1.64). On the 384 other hand, statin initiation was less likely among women compared to men (adjusted 385 OR 0.70, 95% CI, 0.68 – 0.72) and in the black group compared to the white group 386 (adjusted OR 0.71, 95% CI, 0.65-0.77). We also found that the factors associated with 387 initiation were similar across CVD subtypes (Supplementary Figure 5). 388

389

## Figure 4

## 390 **Discontinuation**

Among people who initiated a statin for primary prevention, 26.3% and 37.2% had 391 discontinued statins by 1 year and 5 years of initiation, respectively. For secondary 392 prevention, 10.0% and 19.9% had discontinued statins by 1 year and 5 years of 393 initiation, respectively. We found that statin discontinuation was least likely in the 70+ 394 year age group compared to the 25-39 age group (adjusted HR 0.65, 95% CI; 0.63 -395 396 0.67) and slightly less likely among women compared to men (adjusted HR 0.97, 95%) CI; 0.95 – 0.98) after adjusting for age, gender, ethnicity, and deprivation in the primary 397 prevention cohort (Figure 5). Conversely, statin discontinuation was higher in the black 398 group than the white group (adjusted HR 1.63, 95% CI; 1.59 – 1.68) and in the most 399 deprived group compared with the least deprived group (adjusted HR 1.16, 95% CI; 400 1.14 – 1.18). In line with primary prevention findings, statin discontinuation among 401 those with a history of CVD was most likely among people of black ethnicity compared 402 to those of white ethnicity (adjusted HR 1.76, 95% CI; 1.65 – 1.89) and the most 403 deprived group compared to the least deprived group (HR 1.08, 95% CI; 1.04 – 1.12) 404 however women were also more likely to discontinue than men (HR 1.08, 95% CI; 1.06 405 - 1.11). Findings were also consistent with those according to CVD subtypes 406 (Supplementary Figure 6). Kaplan Meier curves in Supplementary Figures 7 and 8 show 407 that the time to statin discontinuation for primary and secondary prevention was 408 shortest among the youngest age-groups, those of Black ethnicity, the most deprived 409 socioeconomic groups, those with a CVD risk score below threshold (primary 410 411 prevention only) and those with peripheral arterial disease (secondary prevention only). In addition, the curves were steepest for those with CVD risk score below 412 threshold for initiation (primary prevention only) and for peripheral arterial disease 413 (secondary prevention only). 414

## 415

## Figure 5

## 416 **Re-initiation**

For both primary and secondary prevention, older people particularly those in the 70+ 417 418 age group compared to 25-39 group, people of South Asian, black and mixed ethnicity compared to white people and people in the most deprived groups compared to the 419 least deprived groups were most likely to restart statins with statin re-initiation highest 420 in the 70+ age group compared to 25-39 age group adjusted HR 1.39 (95% CI, 1.25 -421 1.55) for secondary prevention(Supplementary Figure 9). Women were less likely to re-422 initiate statins compared to men particularly for secondary prevention HR 0.87 (95% 423 424 CI, 0.85 – 0.90). Similar associations were seen for all CVD subtypes except peripheral arterial disease (Supplementary Figure 10) and Kaplan-Meier curves depicting time 425 426 from statin discontinuation to re-initiation are presented in Supplementary Figures 11 and 12). 427

428

## Table 2

# Number of CVD events prevented with optimal statin use and healthcare costs saved

Table 2 depicts the number of cardiovascular events that could be avoided based on
current and 100% statin prevalence among those eligible for primary and secondary
prevention. For primary prevention, 102,306 additional cardiovascular events would be
prevented over 10 years if all eligible individuals were taking statins across England.
For secondary prevention, 51,495 additional cardiovascular events could be prevented
in England over 5 years if all individuals eligible were taking statins. If all CVD events
from people currently not taking statins are avoided, £265.6 million, including the net

438 cost of statins, can be saved for the NHS for primary prevention and £139.8 million can
439 be saved for secondary prevention (Supplementary Table 6).

## 440 Additional secondary and sensitivity analyses

441 In additional secondary analyses, we stratified our main analyses by pre-pandemic and pandemic periods as shown in Supplementary Figures 13-16. These findings were 442 broadly similar in the pre-pandemic and pandemic periods with larger confidence 443 levels, owing to the smaller sample size, seen in the pandemic periods. Our sensitivity 444 analyses were consistent with our main analyses as we observed minimal changes to 445 446 our effect estimates (Supplementary Figures 17 and 18). Due to evidence of non-447 proportionality (Schoenfeld residuals test, p<0.05) for our Cox proportional hazards analyses on the association of demographic variables and risk of receiving a CVD risk 448 449 assessment, statin discontinuation and statin initiation, we performed additional sensitivity analyses shown in Supplementary Tables 7-10. We found that risk of 450 451 receiving a CVD was higher in the first 5 years from the start of follow up while individuals were less like to receive a CVD risk assessment more than 5 years after start 452 of follow up. Statin discontinuation was less likely in the first 6 months of statin 453 initiation in older age groups compared to more than 6 months and statin 454 455 discontinuation was more likely among ethnic minority groups in the first 6 months than after 6 months for primary prevention with similar findings seen for secondary 456 457 prevention. Analyses on re-initiation were consistent with our primary analysis.

458

459

## 460 **Discussion**

In our comprehensive population-based cohort study of 5 million adults in England, we 461 report the following key findings: 1) between May 2009 and November 2021, we saw an 462 increase in statin prevalence for primary and secondary prevention among the 70+ age 463 group while CVD risk assessment rose steadily over time from 15% to 32%, 2) the 464 monthly prevalence of statins was lowest among black, mixed and other ethnicity and 465 466 those in the most deprived socioeconomic quintile, however these groups, including people of south Asian ethnicity were more likely to receive a CVD risk assessment 467 compared to the white ethnic group and least deprived groups, respectively, 3) 79.0% 468 of individuals were initiated statins within 60 days of a CVD event. Statin initiation for 469 secondary prevention was highest among people of South Asian ethnicity compared to 470 those of white ethnicity but least likely among the black ethnic group compared to 471 white ethnic group and among women compared to men, 4) 26.3% and 10.0% of 472 individuals had discontinued statins within a year of statin initiation for primary and 473 secondary prevention, respectively. Black people, the most deprived socioeconomic 474 group and women (secondary prevention only) were most likely to discontinue statins 475 compared to white people, least deprived groups, and men, respectively. These same 476 groups including people of south Asian ethnicity and the 70+ age group compared to the 477 white and 25-39 groups, respectively, were most likely to re-initiate statins for both 478 primary and secondary prevention, 5) with optimal statin use among those eligible, 479 around 100,000 additional cardiovascular events would be prevented over 10 years for 480 481 primary prevention and 50,000 additional events over 5 years for secondary prevention. This would result in NHS healthcare cost savings of over £400 million. 482

## 483 **Comparison with other studies**

Our prevalence estimates are in line with a UK primary care study which observed a 484 slowed rate of increase in statin prescription rates from 2007 onwards.(34) 485 Cardiovascular risk scoring increased over time in our study, consistent with previous 486 studies, however we observed a decline in recorded risk scores during the pandemic 487 period.(7, 35) The COVID-19 pandemic severely impacted primary care services, with a 488 substantial reduction in primary care contacts for CVD after the introduction of 489 population-wide restrictions.(36) In agreement with our findings, between 2019/20 490 and 2020/21, the proportion of people invited for an NHS Health Check declined by 491 82% with the proportion of people taking up an NHS Health Check invite also declining 492 by 84%, leading to a backlog and suboptimal care. (37-39) Prior to the pandemic, 493 findings from a systematic review showed inequalities in the NHS health check with 494 coverage and uptake higher among older age groups and females between 2009 and 495 2016.(40) Similarly, we found that women and older age groups were more likely to 496 receive a CVD risk assessment, which is part of the NHS health check. Inequalities in 497 CVD risk assessment have implications for statin use as receiving a CVD risk assessment 498 increases the likelihood of a statin prescription.(10) 499

We found that statin initiation was less likely in older age groups compared to the 40-49 500 age group, in our primary prevention cohort among people with a recorded CVD risk 501 score. This finding is in conflict with an English study using The Health Improvement 502 Network (THIN) primary care data which found that statin initiation rate increased with 503 age up to 70-74 years old. (41) Unlike our study, the THIN study did not restrict the 504 505 study population to those with a CVD risk score above threshold for statin initiation. Conditioning on statin eligibility threshold in our study may have resulted in other 506 507 factors associated with statin initiation being more predictive of initiation than age which may explain the differences in findings. Among people with CVD, our findings 508

were consistent with other studies which found that women and black people were less 509 likely to initiate lipid-lowering drugs than men and white people, respectively, while the 510 south Asian ethnic group is more likely to initiate statins compared to the white 511 group.(42, 43) Previous studies have shown that statins are less likely to be prescribed 512 in black ethnic groups compared to white ethnic groups. (44, 45) Similarly, our 513 secondary prevention results of a lack of association between deprivation and statin 514 initiation is consistent with another UK study. (42) 515 We found that a high proportion of those who discontinued statins re-initiated which is 516 in agreement with a Scottish CPRD study that found that 72% and 75% of those who 517 discontinued for primary and secondary prevention, respectively, also re-initiated 518 statins. Consistent with our findings, the authors also reported that women and black, 519 south Asian and other ethnic minority groups were more likely to discontinue statins 520 compared to men and the white ethnic group, respectively.(46) For statin re-initiation, 521 the study also found that women were less likely to re-initiate statins for secondary 522

523 prevention than men while black and Asian groups were more likely to re-initiate

524 statins than white group.(46)

Ethnic differences observed in our study may be a result of residual confounding as we 525 526 were unable to account for factors such as cholesterol levels due to high level of missingness or understand the reasons for under-prescribing and discontinuation of 527 528 statins. A previous UK study found that most patients initiated on statins had no previous CVD risk score. In the absence of a CVD risk score, cholesterol levels were 529 found to be the main predictor of statin initiation.(7, 47) Prior studies have reported 530 that people of black ethnicity are associated with lower than expected rates of access to 531 and use of NHS cardiovascular care. (48) Evidence suggests that healthcare 532

professionals experience considerable uncertainty in supporting ethnically diverse
patients which leads to hesitance and contributes to ethnic health care inequalities. (49)
Structural racism, discrimination and distrust have also been identified as key factors
that negatively impact healthcare. (50) Deprivation has also been associated with CVD,
with people living in the most deprived areas four times more likely to die prematurely
from cardiovascular diseases. (51)

539 Statin discontinuation could have been affected by statin intensity as high-intensity

540 statins could potentially increase the risk of side effects. However, a recent study in

541 Scotland found that discontinuation was less likely in those treated with high intensity

542 statins compared to moderate intensity.(52) Further studies are needed to explore this

543 link in England. Additionally, concerns on the risks and benefits of statins, particularly

544 following media coverage, may have contributed to an increase in statin

545 discontinuation.(53)

## 546 Strengths and Limitations

Our large cohort of 5 million individuals is the first to comprehensively assess
inequalities across all stages of statin use in England for primary and secondary
prevention to the best of our knowledge. Other strengths of our study include a long
follow-up period of 13 years and the use of linked primary and secondary electronic
records broadly representative of the UK population in terms of age, gender, ethnicity

and geographical location and well recorded GP prescription data.(54)

553 There were several limitations in our study. Firstly, in our cardiovascular risk

assessment, discontinuation, and re-initiation analyses, we did not adjust for non-fixed

covariates such as BMI and smoking status due to a lack of time-updated information on

these factors. Furthermore, data on cholesterol and blood pressure measurements had a

high proportion of missing data thus these factors were not adjusted for in our initiation 557 analyses. As a result, we cannot rule out residual confounding. Secondly, low intensity 558 statins can be purchased over the counter and thus we were not able to capture 559 information on statin use outside of primary care. Third, the reasons for statin 560 discontinuation are not well captured in primary care records thus we were unable to 561 explore this. Fourth, there is no data on whether individuals actually collected their 562 statin prescription or took their medication thus misclassification of statin 563 discontinuation is possible as we cannot be certain of when they discontinued statins. 564 Fifth, estimates on the number of cardiovascular events prevented and costs reduced 565 rely on assumptions such as the cardiovascular risk and cost of hospitalisations 566 remaining constant over time. Sixth, although we assessed changes in statin prescribing, 567 we did not investigate whether there was a change in the incidence of cardiovascular 568 events over time particularly during the COVID-19 pandemic though this has recently 569 been reported.(36) We assessed this for primary prevention by observing changes in 570 CVD risk category over the 13-year study period. 571

## 572 **Conclusion**

We observed inequalities by age, gender, ethnicity and deprivation across multiple
stages of statin use including statin prevalence, CVD risk scoring, initiation,
discontinuation and re-initiation. Optimising statin use among those eligible, could lead
to over 150,000 reduced CVD events leading to substantial NHS savings of over £400
million. Further research is needed to understand the reasons for under prescribing and
discontinuation of statins particularly among women, black ethnic groups and the most
deprived socioeconomic groups.

Our study suggests that there is an opportunity to optimise statin treatment through 580 improving CVD risk assessment. Reductions in CVD risk assessment during the COVID-581 19 pandemic highlights the urgent need to improve uptake of routine CVD risk 582 assessment to minimise missed opportunities for statin treatment thereby reducing 583 preventable CVD events and additional costs to the NHS. This also has implications for 584 pandemic planning to ensure important health services can be maintained during 585 periods of reduced in person contact. Future qualitative studies are also needed to 586 explore drivers of variation in statin adherence to understand which groups of patients 587 are less likely to adhere to treatment and thus should be specifically targeted through 588 education and prescribing strategies to reduce preventable CVD events in these groups. 589 **Contributors:** All authors contributed to the conception and/or design of this study. 590 RM analyses the data and wrote the first draft of the manuscript. All authors were 591 involved in the data interpretation and revision of the manuscript. 592 593 **Funding:** This study was funded by the British Heart Foundation (PG/19/71/34632). Ethical approval: Our study protocol was approved via CPRD's Research Data 594 Governance (RDG) process (study ID 22\_001872). Ethical approval was also obtained 595 from the London School of Hygiene and Tropical Medicine research ethics committee 596 (reference: 28002) 597 Data sharing: Study protocol, analysis codes, codelists and additional results for this 598 study can be accessed at https://github.com/RutendoMuzambi/trends statin use. Data 599 were obtained from the CPRD and are not publicly available. Access to CPRD data is 600 dependent upon approval of a study protocol via CPRD's RDG process (details at 601

602 <u>https://cprd.com/research-applications</u>)

## 603 **Transparency**:

604 The lead author affirms that this manuscript is an honest, accurate, and transparent

account of the study being reported; that no important aspects of the study have been

omitted; and that any discrepancies from the study as planned (and, if relevant,

607 registered) have been explained.

608

## 609 **References**

610 1. World Health Organization. Cardiovascular diseases (CVDs) 2021 [02/04/2024]. Available 611 from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). 612 British Heart Foundation. Facts and Figures 2024 [Available from: 2. https://www.bhf.org.uk/what-we-do/news-from-the-bhf/contact-the-press-office/facts-and-613 614 figures#:~:text=Heart%20and%20circulatory%20diseases%20cause,men%20and%203.6%20million% 615 20women. 616 3. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of 617 more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 618 randomised trials. Lancet. 2010;376(9753):1670-81. 619 Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the 4. 620 evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61. 621 5. NHSBA. Prescription Cost Analysis – England – 2022-23 [Available from: 622 https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-623 cost-analysis-england-2022-23. 624 6. Tjeerd-Pieter van S, Liam S, Edmond SWN, Ben G, Martin G. The efficiency of cardiovascular 625 risk assessment: do the right patients get statin treatment? Heart. 2013;99(21):1597. 626 7. Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice: a 627 THIN database study. Br J Gen Pract. 2017;67(665):e881-e7. 628 Ueda P, Lung TW-C, Lu Y, Salomon JA, Rahimi K, Clarke P, Danaei G. Treatment gaps and 8. 629 potential cardiovascular risk reduction from expanded statin use in the US and England. PLOS ONE. 630 2018;13(3):e0190688. 631 9. Homer K, Boomla K, Hull S, Dostal I, Mathur R, Robson J. Statin prescribing for primary 632 prevention of cardiovascular disease: a cross-sectional, observational study. Br J Gen Pract. 633 2015;65(637):e538-44. 634 10. Chang KC, Soljak M, Lee JT, Woringer M, Johnston D, Khunti K, et al. Coverage of a national 635 cardiovascular risk assessment and management programme (NHS Health Check): Retrospective 636 database study. Prev Med. 2015;78:1-8. 637 11. Millett C, Gray J, Saxena S, Netuveli G, Khunti K, Majeed A. Ethnic disparities in diabetes 638 management and pay-for-performance in the UK: the Wandsworth Prospective Diabetes Study. PLoS 639 medicine. 2007;4(6):e191. 640 Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin 12. 641 prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and 642 Outcomes Framework'. Journal of public health (Oxford, England). 2007;29(1):40-7.

643 13. Homer K, Boomla K, Hull S, Dostal I, Mathur R, Robson J. Statin prescribing for primary 644 prevention of cardiovascular disease: a cross-sectional, observational study. The British journal of 645 general practice : the journal of the Royal College of General Practitioners. 2015;65(637):e538-e44. 646 14. Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T. Patient Factors Influencing the Prescribing 647 of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A 648 National Retrospective Cohort Study. PLOS ONE. 2013;8(7):e67611. 649 15. Finnikin S, Willis BH, Ryan R, Evans T, Marshall T. Factors predicting statin prescribing for 650 primary prevention: a historical cohort study. The British journal of general practice : the journal of 651 the Royal College of General Practitioners. 2021;71(704):e219-e25. 652 16. Millett C, Saxena S, Ng A, Mainous A, 3rd, Majeed A. Socio-economic status, ethnicity and 653 diabetes management: an analysis of time trends using the health survey for England. Journal of 654 public health (Oxford, England). 2007;29(4):413-9.

655 Murphy C, Bennett K, Fahey T, Shelley E, Graham I, Kenny RA. Statin use in adults at high risk 17. 656 of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish 657 Longitudinal Study on Ageing (TILDA). BMJ Open. 2015;5(7):e008017.

658 18. Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance 659 and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459-66.

660 19. Thompson W, Morin L, Jarbøl DE, Andersen JH, Ernst MT, Nielsen JB, et al. Statin 661 Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA Network Open. 662 2021;4(12):e2136802-e.

663 20. Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, Myles P. Data resource profile: 664 Clinical Practice Research Datalink (CPRD) Aurum. International Journal of Epidemiology. 665 2019;48(6):1740-g.

Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data Resource Profile: Hospital 666 21. 667 Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol. 2017;46(4):1093-i.

668 22. CPRD. CPRD Aurum January 2022 Dataset 2023 [Available from: https://cprd.com/cprd-669 aurum-january-2022-dataset.

670 23. Nicholls SG, Langan SM, Sørensen HT, Petersen I, Benchimol EI. The RECORD reporting 671 guidelines: meeting the methodological and ethical demands of transparency in research using 672 routinely-collected health data. Clin Epidemiol. 2016;8:389-92.

673 John R, Isabel D, Aziz S, Sandra E, Vichithranie M, Chris G, et al. The NHS Health Check in 24. 674 England: an evaluation of the first 4 years. BMJ Open. 2016;6(1):e008840.

675 25. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and 676 validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective 677 open cohort study. Bmj. 2007;335(7611):136.

678 26. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. 679 Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. 680 Bmj. 2008;336(7659):1475-82.

681 Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, Levy D. 27. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 682 683 2004;94(1):20-4.

684 28. de la Iglesia B, Potter JF, Poulter NR, Robins MM, Skinner J. Performance of the ASSIGN 685 cardiovascular disease risk score on a UK cohort of patients from general practice. Heart.

686 2011;97(6):491-9.

687 29. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification 688 [Available from: https://www.nice.org.uk/guidance/cg181.

689 30. England N. National Cost Collection for the NHS 2022 [Available from:

690 https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/.

691 31. NHSBA. Prescription Cost Analysis - England - 2021/22 2022 [Available from:

692 https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-

693 cost-analysis-england-202122.

694 32. Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and 695 safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 2019;393(10170):407-15. 696 697 33. Office for National Statistics. Census 2023 [Available from: https://www.ons.gov.uk/census. 698 34. O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary 699 prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health 700 Improvement Network primary care data. Clin Epidemiol. 2016;8:123-32. 701 35. Pate A, Emsley R, Staa Tv. Impact of lowering the risk threshold for statin treatment on statin 702 prescribing: a descriptive study in English primary care. British Journal of General Practice. 703 2020;70(700):e765-e71. 704 36. Mansfield KE, Mathur R, Tazare J, Henderson AD, Mulick AR, Carreira H, et al. Indirect acute 705 effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based 706 study. Lancet Digit Health. 2021;3(4):e217-e30. 707 Public Health England. NHS Health Check - Data - People invited for an NHS Health Check per 37. 708 year 2024 [Available from: https://fingertips.phe.org.uk/profile/nhs-health-check-709 detailed/data#page/4/gid/1938132726/pat/159/par/K02000001/ati/15/are/E92000001/iid/91733/a ge/219/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1/page-options/tre-do-0. 710 711 38. Public Health England. NHS Health Check - Data - People taking up an NHS Health Check 712 invite per year 2024 [Available from: https://fingertips.phe.org.uk/profile/nhs-health-check-713 detailed/data#page/4/gid/1938132726/pat/159/par/K0200001/ati/15/are/E92000001/iid/91735/a 714 ge/219/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1/page-options/tre-do-0. 715 39. Levene LS, Seidu S, Greenhalgh T, Khunti K. Pandemic threatens primary care for long term 716 conditions. BMJ. 2020;371:m3793. 717 40. Martin A, Saunders CL, Harte E, Griffin SJ, MacLure C, Mant J, et al. Delivery and impact of 718 the NHS Health Check in the first 8 years: a systematic review. British Journal of General Practice. 719 2018;68(672):e449-e59. 720 O'Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary 41. 721 prevention of cardiovascular disease: an assessment of differences between countries of the UK and 722 between regions within England. BMJ Open. 2015;5(3):e007207. 723 42. Mathur R, Badrick E, Boomla K, Bremner S, Hull S, Robson J. Prescribing in general practice 724 for people with coronary heart disease; equity by age, sex, ethnic group and deprivation. Ethnicity & 725 Health. 2011;16(2):107-23. Carey IM, DeWilde S, Shah SM, Harris T, Whincup PH, Cook DG. Statin use after first 726 43. 727 myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued 728 treatment? Nutrition, Metabolism and Cardiovascular Diseases. 2012;22(5):400-8. 729 44. Millett C, Gray J, Wall M, Majeed A. Ethnic disparities in coronary heart disease management 730 and pay for performance in the UK. J Gen Intern Med. 2009;24(1):8-13. 731 Eastwood SV, Mathur R, Sattar N, Smeeth L, Bhaskaran K, Chaturvedi N. Ethnic differences in 45. guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006–2019: A 732 733 cohort study. PLOS Medicine. 2021;18(6):e1003672. 734 46. Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in 735 patients on statin treatment: prospective open cohort study using a primary care database. BMJ. 736 2016;353:i3305. 737 47. Finnikin S, Willis BH, Ryan R, Evans T, Marshall T. Factors predicting statin prescribing for 738 primary prevention: a historical cohort study. Br J Gen Pract. 2021;71(704):e219-e25. 739 Asthana S, Moon G, Gibson A, Bailey T, Hewson P, Dibben C. Inequity in cardiovascular care 48. 740 in the English National Health Service (NHS): a scoping review of the literature. Health & Social Care 741 in the Community. 2018;26(3):259-72. 742 49. Kai J, Beavan J, Faull C, Dodson L, Gill P, Beighton A. Professional uncertainty and 743 disempowerment responding to ethnic diversity in health care: a qualitative study. PLoS Med. 744 2007;4(11):e323.

745 50. Danso A, Danso Y. The complexities of race and health. Future Healthc J. 2021;8(1):22-7.

Public Health England. Health Inequalities Dashboard: statistical commentary, March 2021 746 51. 747 2021 [Available from: https://www.gov.uk/government/statistics/health-inequalities-dashboard-748 march-2021-data-update/health-inequalities-dashboard-statistical-commentary-march-2021.

749 Rezende Macedo do Nascimento RC, Mueller T, Godman B, MacBride Stewart S, Hurding S, 52. 750 de Assis Acurcio F, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study. British Journal of Clinical Pharmacology. 751 752 2020;86(12):2349-61.

753 53. Matthews A, Herrett E, Gasparrini A, Staa TV, Goldacre B, Smeeth L, Bhaskaran K. Impact of 754 statin related media coverage on use of statins: interrupted time series analysis with UK primary 755 care data. BMJ. 2016;353:i3283.

756 Shiekh SI, Harley M, Ghosh RE, Ashworth M, Myles P, Booth HP, Axson EL. Completeness, 54. 757 agreement, and representativeness of ethnicity recording in the United Kingdom's Clinical Practice 758 Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). Population Health Metrics. 759 2023;21(1):3.

760

761

762

## 763 **TABLES AND FIGURES**

## 764 Table 1A: Baseline Characteristics of individuals included in the prevalence, initiation, discontinuation and re-initiation cohorts for

765 primary prevention

	Total Cohort	Prevalence	Initiation	Discontinuation	Re-initiation
Total (N)	4606274	4597500	432686	303292	116468
Median Age (years, IQR)	39.0 (29.0 to 53.0)	39.0 (29.0 to 53.0)	59.0 (52.0 to 64.0)	57.0 (48.0 to 65.0)	56.0 (47.0 to 64.0)
Mean Age (years)	43.1 (16.3)	43.1 (16.3)	58.1 (8.5)	56.4 (12.0)	55.3 (12.1)
Age Group (years)					
25-39	2438046 (52.9)	2437488 (53.0)	11617 (2.7)	30503 (10.1)	13814 (11.9)
40-49	826872 (18.0)	825401 (18.0)	73928 (17.1)	65955 (21.7)	27651 (23.7)
50-59	577159 (12.5)	574625 (12.5)	159485 (36.9)	88711 (29.2)	33158 (28.5)
60-69	406956 (8.8)	404167 (8.8)	162679 (37.6)	82383 (27.2)	29803 (25.6)
70-79	223390 (4.8)	222263 (4.8)	24977 (5.8)	29727 (9.8)	10460 (9.0)
80+	133851 (2.9)	133556 (2.9)	0 (0.0)	6013 (2.0)	1582 (1.4)
Gender					
Men	2266027 (49.2)	2261032 (49.2)	270384 (62.5)	160423 (52.9)	62833 (53.9)
Women	2340247 (50.8)	2336468 (50.8)	162302 (37.5)	142869 (47.1)	53635 (46.1)
Ethnicity					
White	3466710 (75.3)	3459201 (75.2)	373497 (86.3)	257561 (84.9)	93676 (80.4)
South Asian	355343 (7.7)	354653 (7.7)	30719 (7.1)	23054 (7.6)	11823 (10.2)
Black	212500 (4.6)	212261 (4.6)	11791 (2.7)	10293 (3.4)	5809 (5.0)
Mixed	69483 (1.5)	69402 (1.5)	2601 (0.6)	2340 (0.8)	1166 (1.0)
Other	143355 (3.1)	143206 (3.1)	4577 (1.1)	3896 (1.3)	1815 (1.6)
Missing	358883 (7.8)	358777 (7.8)	9501 (2.2)	6148 (2.0)	2179 (1.9)
Deprivation					
1. Least deprived	824622 (17.9)	823082 (17.9)	96920 (22.4)	63781 (21.0)	22290 (19.1)
2	823305 (17.9)	821586 (17.9)	91634 (21.2)	62264 (20.5)	22118 (19.0)
3	836752 (18.2)	834935 (18.2)	80348 (18.6)	58161 (19.2)	21530 (18.5)
4	905218 (19.7)	903485 (19.7)	75344 (17.4)	56091 (18.5)	22125 (19.0)
5. Most Deprived	1209860 (26.3)	1207909 (26.3)	88034 (20.3)	62719 (20.7)	28312 (24.3)
Missing	6517 (0.1)	6503 (0.1)	406 (0.1)	276 (0.1)	93 (0.1)
Baseline BMI, kg/m2					
Underweight (<18·5)	103178 (2.2)	103099 (2.2)	3254 (0.8)	2387 (0.8)	863 (0.7)
Normal weight (18·5–24·9)	1785114 (38.8)	1783078 (38.8)	119720 (27.7)	82732 (27.3)	31483 (27.0)

Overweight (25·0–29·9)	1297608 (28.2)	1294388 (28.2)	172946 (40.0)	116778 (38.5)	45303 (38.9)		
Obese or morbidly obese							
(≥30.0)	825131 (17.9)	821795 (17.9)	130797 (30.2)	96878 (31.9)	37375 (32.1)		
Missing	595243 (12.9)	595140 (12.9)	5969 (1.4)	4517 (1.5)	1444 (1.2)		
Smoking Status							
Non-smoker	1588277 (34.5)	1586733 (34.5)	88802 (20.5)	66595 (22.0)	25303 (21.7)		
Current smoker	1399899 (30.4)	1396575 (30.4)	150028 (34.7)	101446 (33.4)	40840 (35.1)		
Former smoker	1463110 (31.8)	1459214 (31.7)	192658 (44.5)	134624 (44.4)	50170 (43.1)		
Missing	595243 (12.9)	154978 (3.4)	1198 (0.3)	627 (0.2)	155 (0.1)		
Systolic blood pressure	125.6 (15.9)	125.6 (15.9)	134.4 (15.0)	134.0 (15.6)	133.6 (15.9)		
Diastolic blood pressure	76.3 (9.9)	76.3 (9.9)	80.6 (9.2)	80.4 (9.5)	80.5 (9.6)		
HDL	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)		
LDL	3.0 (1.0)	3.0 (1.0)	3.2 (1.0)	3.6 (0.9)	3.6 (0.9)		
TCHL	5.1 (1.1)	5.1 (1.1)	5.3 (1.1)	5.7 (1.0)	5.8 (1.1)		
THDL	3.8 (1.3)	3.8 (1.3)	4.2 (1.3)	4.4 (1.3)	4.5 (1.3)		
Hypertension	592472 (12.9)	588428 (12.8)	142163 (32.9)	89459 (29.5)	32695 (28.1)		
Treated Hypertension	374491 (8.1)	371753 (8.1)	92290 (21.3)	51628 (17.0)	18692 (16.0)		
Type II diabetes mellitus	183683 (4.0)	182246 (4.0)	42879 (9.9)	21432 (7.1)	8880 (7.6)		
Atrial Fibrillation	55364 (1.2)	54847 (1.2)	7941 (1.8)	6408 (2.1)	2081 (1.8)		
Chronic kidney disease	121868 (2.6)	121206 (2.6)	5501 (1.3)	13361 (4.4)	4712 (4.0)		
Rheumatoid Arthritis	36486 (0.8)	36293 (0.8)	7828 (1.8)	4873 (1.6)	1839 (1.6)		
The prevalence cohort includes individuals aged 25 years and older without pre-existing cardiovascular disease who are alive on or after 30/04/2009. This							
allowed for a grace period of 28 days between prescriptions in order to define a current statin user as having an ongoing statin prescription based on the							
number of days prescribed.							

766

## Table 1B: Baseline Characteristics of individuals included in the prevalence, initiation, discontinuation and re-initiation cohorts for secondary prevention

	Total	Prevalence	Initiation	Discontinuation	Re-initiation
Total (N)	416431	406746	146811	122743	27257
Median Age (years, IQR)	70.0 (59.0 to 79.0)	70.0 (59.0 to 79.0)	63.0 (53.0 to 73.0)	63.0 (53.0 to 72.0)	61.0 (51.0 to 70.0)
Mean Age (years)	68.5 (14.1)	68.6 (14.1)	62.9 (13.7)	62.4 (12.9)	60.9 (12.6)
Age Group (years)					
25-39	12870 (3.1)	12537 (3.1)	7995 (5.4)	5591 (4.6)	1447 (5.3)
40-49	35598 (8.5)	34515 (8.5)	21298 (14.5)	18331 (14.9)	4745 (17.4)

50-59	67340 (16.2)	65377 (16.1)	32368 (22.0)	29006 (23.6)	6800 (24.9)
60-69	102060 (24.5)	99424 (24.4)	38993 (26.6)	34557 (28.2)	7521 (27.6)
70-79	108820 (26.1)	106328 (26.1)	31229 (21.3)	25738 (21.0)	5329 (19.6)
80+	89743 (21.6)	88565 (21.8)	14928 (10.2)	9520 (7.8)	1415 (5.2)
Gender					
Men	236791 (56.9)	231886 (57.0)	84143 (57.3)	73375 (59.8)	16372 (60.1)
Women	179640 (43.1)	174860 (43.0)	62668 (42.7)	49368 (40.2)	10885 (39.9)
Ethnicity					
White	378677 (90.9)	369887 (90.9)	132765 (90.4)	110629 (90.1)	23956 (87.9)
South Asian	19333 (4.6)	18828 (4.6)	7410 (5.0)	6720 (5.5)	1793 (6.6)
Black	8469 (2.0)	8269 (2.0)	3301 (2.2)	2657 (2.2)	889 (3.3)
Mixed	2010 (0.5)	1961 (0.5)	805 (0.5)	665 (0.5)	167 (0.6)
Other	3238 (0.8)	3152 (0.8)	1191 (0.8)	997 (0.8)	265 (1.0)
Missing	4704 (1.1)	4649 (1.1)	1339 (0.9)	1075 (0.9)	187 (0.7)
Deprivation					
1. Least deprived	89102 (21.4)	87074 (21.4)	32581 (22.2)	26950 (22.0)	5626 (20.6)
2	89132 (21.4)	87139 (21.4)	31807 (21.7)	26453 (21.6)	5710 (20.9)
3	84599 (20.3)	82633 (20.3)	29476 (20.1)	24526 (20.0)	5414 (19.9)
4	79045 (19.0)	77214 (19.0)	27114 (18.5)	22817 (18.6)	5158 (18.9)
5. Most Deprived	73960 (17.8)	72102 (17.7)	25687 (17.5)	21887 (17.8)	5323 (19.5)
Missing	593 (0.1)	584 (0.1)	146 (0.1)	110 (0.1)	26 (0.1)
Baseline BMI, kg/m2					
Underweight (<18·5)	8111 (1.9)	7984 (2.0)	2050 (1.4)	1430 (1.2)	346 (1.3)
Normal weight (18·5–24·9)	120889 (29.0)	118335 (29.1)	43665 (29.7)	35052 (28.6)	8030 (29.5)
Overweight (25·0–29·9)	153583 (36.9)	150061 (36.9)	56271 (38.3)	48256 (39.3)	10606 (38.9)
Obese or morbidly obese					
(≥30.0)	115987 (27.9)	112663 (27.7)	41079 (28.0)	35602 (29.0)	7822 (28.7)
Missing	17861 (4.3)	17703 (4.4)	3746 (2.6)	2403 (2.0)	453 (1.7)
Smoking Status					
Non-smoker	78143 (18.8)	76470 (18.8)	27563 (18.8)	21603 (17.6)	4425 (16.2)
Current smoker	131105 (31.5)	127689 (31.4)	52726 (35.9)	45535 (37.1)	11021 (40.4)
Former smoker	205381 (49.3)	200795 (49.4)	66239 (45.1)	55450 (45.2)	11791 (43.3)
Missing	1802 (0.4)	1792 (0.4)	283 (0.2)	155 (0.1)	20 (0.1)
Systolic blood pressure	134.1 (16.6)	134.0 (16.6)	136.1 (16.2)	136.3 (15.9)	136.3 (16.5)
Diastolic blood pressure	76.5 (10.2)	76.5 (10.2)	79.2 (9.9)	79.4 (9.8)	80.0 (10.0)

HDL	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)	1.4 (0.5)		
LDL	2.6 (1.0)	2.6 (1.0)	3.1 (1.0)	3.1 (1.0)	3.2 (1.0)		
TCHL	4.7 (1.2)	4.7 (1.2)	5.2 (1.2)	5.2 (1.2)	5.4 (1.2)		
THDL	3.7 (1.2)	3.7 (1.2)	4.0 (1.3)	4.1 (1.4)	4.2 (1.4)		
Hypertension	248691 (59.7)	242841 (59.7)	69240 (47.2)	57956 (47.2)	12444 (45.7)		
Treated Hypertension	185192 (44.5)	181085 (44.5)	43617 (29.7)	36874 (30.0)	7684 (28.2)		
Type II diabetes mellitus	83906 (20.1)	81394 (20.0)	21737 (14.8)	19495 (15.9)	4255 (15.6)		
Atrial Fibrillation	55709 (13.4)	54771 (13.5)	10701 (7.3)	7718 (6.3)	24435 (89.6)		
Chronic kidney disease	86709 (20.8)	84909 (20.9)	17721 (12.1)	13897 (11.3)	2822 (10.4)		
Rheumatoid Arthritis	10677 (2.6)	10396 (2.6)	3426 (2.3)	2677 (2.2)	615 (2.3)		
CVD Subtype							
Myocardial Infarction	71813 (17.2)	70554 (17.3)	27700 (18.9)	26342 (21.5)	4670 (17.1)		
Stroke	78550 (18.9)	76253 (18.7)	33291 (22.7)	26798 (21.8)	5130 (18.8)		
Angina	70555 (16.9)	69182 (17.0)	18760 (12.8)	15316 (12.5)	3742 (13.7)		
Peripheral Arterial Disease	44043 (10.6)	42565 (10.5)	17725 (12.1)	13998 (11.4)	4015 (14.7)		
Transient Ischaemic Attack	38758 (9.3)	37718 (9.3)	17770 (12.1)	14542 (11.8)	3696 (13.6)		
Cerebrovascular							
procedures	211 (0.1)	210 (0.1)	95 (0.1)	85 (0.1)	22 (0.1)		
The prevalence cohort includes individuals aged 25 years and older with prior CVD who are alive on or after 30/04/2009.							





CVD Angina — Myocardial Infarction Peripheral Arterial D Transient Ischeamic Attack Stroke

772

773

Monthly proportion of statin users from May 2009 to November 2021 for primary and secondary prevention of cardiovascular disease. A. represents the primary prevention population and the denominator for this cohort are individuals without a history of cardiovascular disease. B. represents the secondary prevention population and the denominator for this cohort are individuals a cardiovascular disease diagnosis.

#### 774 Figure 3. Adjusted hazard ratios for factors associated with receiving a recorded CVD risk assessment 775

776



## 777

Hazard ratios from Cox proportional hazards regression model for the association between demographic factors and receiving a cardiovascular risk assessment, adjusted for gender, ethnicity and deprivation with age as the underlying time scale. Abbreviations: CI, confidence interval; HR, Hazard Ratio.

#### 781 Figure 4: Odds ratios for the factors associated with statin initiation for primary and secondary prevention 782



783

784

Odds ratios for factors associated with statin initiation for primary and secondary prevention. A. Primary prevention population which includes individuals with an above threshold GP recorded CVD risk score with statin initiation defined as having a statin prescription within 28 days of CVD risk score. B. Secondary prevention population comprising of individuals with a first CVD diagnosis during study period with statin initiation defined as having a statin prescription within 60 days of CVD diagnosis.

#### 785 Figure 5. Adjusted Hazard Ratios for factors associated with statin discontinuation for 786 primary and secondary CVD prevention.



## 787

788

Hazard ratios from cox proportional hazards regression models for the association between demographic factors and statin discontinuation (defined as reaching the end of a 90-day grace period without a new prescription) adjusted for gender, ethnicity and deprivation with age as the underlying time scale. A. represents the primary prevention cohort which includes individuals aged 25 years and older who initiated statins without history of cardiovascular disease. Analyses are stratified by pre-pandemic period (before 1st March 2020 and pandemic period (1st March 2020 onwards). B. represents the cohort with a history of cardiovascular disease who initiated statins. Abbreviations: CI, confidence interval; HR, Hazard Ratio.

789

#### Table 2. Number of CVD events that can be prevented with optimal statin use 790

GP recorded Risk category	Number of patients eligible	Current Statin Prevalence	Total number of expected events based on risk score	Events avoided over 10 years based on current prevalence	Events avoided over 10 years based on 100% prevalence	Additional events avoided based on 100% prevalence	Scaled to English population		
10-19%	384980	43%	53660	13415	5828	7587	60726		
20-29%	144948	65%	34928	8732	5719	3013	24113		
30+%	84656	73%	32855	8214	6032	2182	17466		
Total	614584	53%	88588	30361	17578	12783	102306		
Secondary Prevention based on 10% absolute risk benefit over 5 vears <sup>b</sup>									

## Primary Prevention based on 25% risk reduction<sup>a</sup>

### у

CVD subtype	Number of patients eligible	Current Statin Prevalence	Events avoided over 5 years based on current prevalence	Events avoided over 5 years based on 100% prevalence	Additional events avoided based on 100% prevalence	Scaled to English population
MI	73855	88%	6464	7386	922	7379
Angina	71783	80%	5734	7178	1445	11565
TIA	39052	77%	3009	3905	896	7171
Stroke	44492	76%	3402	4449	1047	8380
PAD	81278	74%	6004	8128	2124	17000
Total	310460	79%	24612	31046	6434	51495

a. risk reduction over 10 years for non-vascular disease derived from Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61. b. 10% absolute risk benefit over 5 years derived from Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 2019;393(10170):407-15. MI; Myocardial Infarction, TIA; Transient Ischaemic Attack, PAD; Peripheral Arterial Disease